Tuesday, December 22, 2020 5:53:03 PM
The results are much better that what PR said. Slide 14-15 shows correct numbers which were clarified by them.
Real numbers
Total patients - 31
Total BBS patients - 28
No of patients dropped - 4
Total no of patients relevant - 24
No of patients with 5%+ weight reduction - 16 = 67% that is double the number compared to combined number of 34.5%
No of patients who lost more than 10% weight - 11 out of 24 (45.8%)
Mean reduction - 14.5%
Compared to 1st approval which had few hundred population, BBS has 1000-1500 target population in US alone
This is large population for rare disease - @ $200k per year - this is a big market.
Also this is not a gene therapy - so drug is needed forever and it keeps the weight down.
Last point - All genes targeted in basket trial are in BBS category (strong or very strong relationship) so they think the basket trial results may be positive.
Cash enough till 2022. I think if stock goes down further, it will be good opportunity to buy - stock could give 50% returns from here in 6 months based on basket trial results.
Recent RYTM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 08:21:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/09/2024 08:17:00 PM
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants • GlobeNewswire Inc. • 05/09/2024 08:01:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:43:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:10:20 AM
- Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update • GlobeNewswire Inc. • 05/07/2024 11:00:00 AM
- Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology • GlobeNewswire Inc. • 04/29/2024 10:30:00 PM
- Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • GlobeNewswire Inc. • 04/24/2024 08:01:00 PM
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants • GlobeNewswire Inc. • 04/16/2024 08:01:00 PM
- Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing • GlobeNewswire Inc. • 04/01/2024 12:00:00 PM
- Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants • GlobeNewswire Inc. • 03/11/2024 08:01:00 PM
- Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences • GlobeNewswire Inc. • 03/06/2024 09:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/29/2024 09:58:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:46:06 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:44:28 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/29/2024 09:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:01:26 PM
- Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan • GlobeNewswire Inc. • 02/22/2024 12:01:00 PM
- Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 12:02:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 12:01:57 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 12:00:59 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/22/2024 12:00:42 AM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM